Hiroshi Ohnishi

Hiroshi Ohnishi

Auto-generated profile, based on publicly available information

Hiroshi Ohnishi

Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kochi, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
YTYusuke Takayama
Yusuke Takayama
HOHiroshi Ohnishi
Hiroshi Ohnishi
FOFumiya Ogasawara
Fumiya Ogasawara
KOKosuke Oyama
Kosuke Oyama
TKTetsuya Kubota
Tetsuya Kubota
AYAkihito Yokoyama
Akihito Yokoyama
Background: Asthma–COPD overlap (ACO) is difficult to diagnose because it is characterized by persistent airflow limitation, and patients present with several manifestations that are usually associated with both asthma and COPD. In this retrospective study, we aimed to evaluate the diagnostic accuracy of fractional exhaled nitric oxide (FeNO) and blood eosinophil counts for the clinical diagnosis of ACO. Patients and methods: A total of 121 patients were divided into two study groups, COPD alone or ACO, which was based on criteria from the joint document by the Global Initiative for Asthma and the Global initiative for chronic Obstructive Lung Disease. From July 2014 to April 2017, FeNO levels and blood eosinophil counts were measured in specimens from patients naïve to inhaled corticosteroids (ICS) and those using ICS. Receiver operating characteristic curve analysis was used to determine the cutoff values of FeNO and blood eosinophil levels that provided the best differential diagnosis between ACO and COPD. Results: Among a total of 121 patients, 65 patients were diagnosed with COPD and 56 patients with ACO. The FeNO level was higher in patients with ACO than in patients with COPD (median 24.5 vs 16.0 ppb, respectively; P<0.01). Among patients naïve to ICS, the area under the receiver operating characteristic curve of FeNO values was 0.726, and the optimal diagnostic cutoff level of FeNO was 25.0 ppb, with 60.6% sensitivity and 87.7% specificity for differentiating ACO from COPD. FeNO (≥25.0 ppb) combined with blood eosinophil counts (≥250/µL) showed 96.1% specificity. Conclusion: These results demonstrate that the FeNO level combined with blood eosinophil count is useful for the differential diagnosis between ACO and COPD.

7 August 2014 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
HOHiroshi Ohnishi
Hiroshi Ohnishi
SMShintaro Miyamoto
Shintaro Miyamoto
SKShigeo Kawase
Shigeo Kawase
TKTetsuya Kubota
Tetsuya Kubota
AYAkihito Yokoyama
Akihito Yokoyama
Serum KL-6 is a useful biomarker for the diagnosis of interstitial lung diseases (ILD). However, KL-6 has not been used to discriminate different types of ILD. Serum KL-6 concentrations can vary depending on antigen exposure levels in patients with hypersensitivity pneumonitis (HP); however, seasonal changes in serum KL-6 concentrations in ILD have not been determined. We hypothesized that seasonal variation of serum KL-6 is greater in HP than for the other ILD. The aim of this study was to determine seasonal variation of serum KL-6 concentrations in various ILD.

16 June 2022 in Heliyon
Verified
Journal Article
Open access
HOHiroshi Ohnishi
Hiroshi Ohnishi
MEMasamitsu Eitoku
Masamitsu Eitoku
AYAkihito Yokoyama
Akihito Yokoyama
Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive pulmonary disease (COPD) patients with increased peripheral blood eosinophils. Clinical trials of biologics that target Type 2 inflammation in COPD were found using PubMed, the Cochrane Library, and ClinicalTrials.gov. We analyzed the clinical efficacy of anti-IL-5-targeted therapy at approved (benralizumab 30 mg, mepolizumab 100 mg, for severe asthma) and high (benralizumab 100 mg, mepolizumab 300 mg) doses. Approved benralizumab and mepolizumab doses tended to reduce moderate-to-severe exacerbations by 9% [risk ratio (RR) 0.91, 95% confidence interval (CI) [0.83, 1.00], p = 0.05], but did not reduce exacerbations requiring emergency department visits or hospitalization. High-dose benralizumab and mepolizumab reduced moderate-to-severe exacerbations by 12% (RR = 0.88, 95% CI [0.80, 0.98], p = 0.02) and exacerbations requiring emergency department visits or hospitalization by 33% (RR = 0.67, 95% CI [0.53, 0.84], p = 0.0005). Neither dose improved St. George's Respiratory Questionnaire or COPD Assessment Test scores. The safety of benralizumab and mepolizumab was comparable to placebo. Benralizumab and mepolizumab have limited efficacy in reducing moderate-to-severe exacerbations in COPD patients with increased peripheral blood eosinophils and requires at least high doses.

15 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TTTsukie Kin Tsukuda
Tsukie Kin Tsukuda
HOHiroshi Ohnishi
Hiroshi Ohnishi
MFMinoru Fujimoto
Minoru Fujimoto
YNYu Nakatani
Yu Nakatani
KTKazufumi Takamatsu
Kazufumi Takamatsu
AYAkihito Yokoyama
Akihito Yokoyama
Progressive fibrosing interstitial lung diseases (PF-ILDs) have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the deterioration of lung function. The aim of this study was to identify the characteristic cellular profile of bronchoalveolar lavage fluid at diagnostic bronchoscopy for predicting PF-ILDs, defined as fibrotic diseases on chest high-resolution computed tomography with more than a 5% relative decline in the percent predicted value of forced vital capacity (FVC) over 6 months. The proportions of inflammatory cells, CCR6−CXCR3− T helper type 2 (Th2) cells among conventional CD4+ T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood, were measured by flowcytometry. The proportion of lymphocytes in BALF was significantly higher in non-PF-ILD patients than in PF-ILD patients. The proportion of Th2 cells in BALF, but not in peripheral blood, was significantly higher in PF-ILD patients than in non-PF-ILD patients. Multivariate analysis showed that a greater population of Th2 cells in BALF was the only indicator for PF-ILDs. An increased proportion of Th2 cells in BALF is associated with greater deterioration of lung function in fibrotic interstitial lung diseases.

1 January 2004 in Internal Medicine
Verified
Journal Article
Open access
PDF file
HOHiroshi Ohnishi
Hiroshi Ohnishi
MAMasahiro Abe
Masahiro Abe
AYAkihito Yokoyama
Akihito Yokoyama
HHHironobu Hamada
Hironobu Hamada
RIRyoji Ito
Ryoji Ito
JHJitsuo Higaki
Jitsuo Higaki
Clarithromycin (CAM) has been widely used for the treatment of respiratory infection. Macrolides are generally well tolerated and their adverse reactions are rare. An 80-year-old woman with nontuberculous mycobacterium infection was treated with combined chemotherapy, including isoniazid, rifampicin, and ethambutol. She developed a fever and peripheral blood eosinophilia, and new subpleural consolidations were observed on chest radiography three days after add-on therapy with CAM. The symptoms and clinical findings improved with the withdrawal of CAM. Histopathologic examinations confirmed the diagnosis of eosinophilic pneumonia. This is the first report of CAM-induced eosinophilic pneumonia.

15 October 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HOHiroshi Ohnishi
Hiroshi Ohnishi
TTTakuya Tanimoto
Takuya Tanimoto
RIRyunosuke Inaba
Ryunosuke Inaba
MEMasamitsu Eitoku
Masamitsu Eitoku